https://vettapharma.com/pharmaceutical-news/fda-eu-approve-gileads-trodelvy-for-first-line-metastatic-triple-negative-breast-cancer/ 2026-06-26T07:46:01Z VETTAPHARMA en FDA, EU Approve Gilead's Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer 2026-06-26T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/canada-approves-abbvies-boey-first-rapid-onset-neurotoxin-for-frown-lines/ 2026-06-26T08:15:45Z VETTAPHARMA en Canada Approves AbbVie's Boey, First Rapid-Onset Neurotoxin for Frown Lines 2026-06-26T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/eu-approves-abbvies-maviret-for-acute-hepatitis-c-virus-infection/ 2026-06-26T08:14:16Z VETTAPHARMA en EU Approves AbbVie's MAVIRET for Acute Hepatitis C Virus Infection 2026-06-26T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/u-s-fda-tentatively-approves-lupins-enzalutamide-tablets/ 2026-06-26T08:42:51Z VETTAPHARMA en U.S. FDA Tentatively Approves Lupin's Enzalutamide Tablets 2026-06-26T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/lilly-completes-centessa-acquisition-to-advance-sleep-disorder-pipeline/ 2026-06-25T13:51:55Z VETTAPHARMA en Lilly Completes Centessa Acquisition to Advance Sleep Disorder Pipeline 2026-06-25T13:51:51Z Blog https://vettapharma.com/pharmaceutical-news/fda-approves-ionis-tryngolza-to-reduce-acute-pancreatitis-risk/ 2026-06-25T13:53:00Z VETTAPHARMA en FDA Approves Ionis' Tryngolza to Reduce Acute Pancreatitis Risk 2026-06-25T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/fda-ema-accept-regenerons-cemdisiran-for-generalized-myasthenia-gravis/ 2026-06-25T13:54:23Z VETTAPHARMA en FDA, EMA Accept Regeneron's Cemdisiran for Generalized Myasthenia Gravis 2026-06-25T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/boehringer-launches-three-phase-3-trials-in-hard-to-treat-cancers/ 2026-06-25T13:55:11Z VETTAPHARMA en Boehringer Launches Three Phase 3 Trials in Hard-to-Treat Cancers 2026-06-25T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/fda-grants-priority-review-to-alexions-ultomiris-for-immunoglobulin-a-nephropathy/ 2026-06-25T13:55:51Z VETTAPHARMA en FDA Grants Priority Review to Alexion's Ultomiris for Immunoglobulin A Nephropathy 2026-06-25T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/merck-appoints-miguel-fernandez-alcalde-as-global-strategy-head-monia-vial-as-emd-serono-president/ 2026-06-25T13:56:13Z VETTAPHARMA en Merck Appoints Miguel Fernández Alcalde as Global Strategy Head, Monia Vial as EMD Serono President 2026-06-25T10:00:00Z Blog https://vettapharma.com/pharmaceutical-news/eu-approves-sanofis-cenrifki-first-disability-targeting-ms-therapy/ 2026-06-24T11:33:13Z VETTAPHARMA en EU Approves Sanofi's Cenrifki, First Disability-Targeting MS Therapy 2026-06-24T12:00:00Z Blog https://vettapharma.com/pharmaceutical-news/japan-approves-sanofis-wayrilz-for-difficult-to-treat-itp/ 2026-06-24T12:04:52Z VETTAPHARMA en Japan Approves Sanofi's Wayrilz for Difficult-to-Treat ITP 2026-06-24T12:00:00Z Blog https://vettapharma.com/pharmaceutical-news/fda-expands-dexcoms-stelo-continuous-glucose-monitor-to-kids/ 2026-06-24T11:44:28Z VETTAPHARMA en FDA Expands Dexcom's Stelo Continuous Glucose Monitor to Kids 2026-06-24T12:00:00Z Blog